

**PART B—ISSUE FEE TRANSMITTAL**

**MAILING INSTRUCTIONS:** This form should be used for transmitting the ISSUE FEE. Blocks 2 through 6 should be completed where appropriate. All further correspondence including the Issue Fee Receipt, the Patent, advance orders and notification of maintenance fees will be mailed to addressee entered in Block 1 unless you direct otherwise, by: (a) specifying a new correspondence address in Block 3 below; or (b) providing the PTO with a separate "FEE ADDRESS" for maintenance fee notifications with the payment of Issue Fee or thereafter. See reverse for Certificate of Mailing, below.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. #7

**Burden Hour Statement:** This form is estimated to take 0.2 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Issue Fee, Assistant Commissioner for Patents, Washington D.C. 20231

1. CORRESPONDENCE ADDRESS

ROBERT S HONOR  
SANDOZ CORPORATION  
59 ROUTE 10  
EAST HANOVER NJ 07936-1000

12M1/1216

DEC 19 1996

PAPER TO BE ENTERED

2. INVENTOR(S) ADDRESS CHANGE (Complete only if there is a change)

INVENTOR'S NAME

Street Address


City, State and ZIP Code

CO-INVENTOR'S NAME

Street Address

City, State and ZIP Code

Check if additional changes are enclosed



APPLICATION NO.	FILING DATE	TOTAL CLAIMS	EXAMINER AND GROUP ART UNIT	DATE MAILED
08/416,673	04/07/95	009	BOND, R 1202	12/16/96
First Named Applicant	COTTENS, SYLVAIN			

TITLE OF INVENTION: O-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE, PARTICULARLY AS IMMUNOSUPPRESSANTS

ATTY'S DOCKET NO.	CLASS-SUBCLASS	BATCH NO.	APPLN. TYPE	SMALL ENTITY	FEE DUE	DATE DUE
1	100-7932/PCT	514-514.000	H50	UTILITY	NO \$1290.00	03/17/97

3. Correspondence address change (Complete only if there is a change)

4. For printing on the patent front page, list the names of not more than 3 registered patent attorneys or agents OR, alternatively, the name of a firm having as a member a registered attorney or agent. If no name is listed, no name will be printed.

1 Robert S. Honor

2 Melvyn M. Kassenoff

3 Thomas O. McGovern

5. ASSIGNMENT DATA TO BE PRINTED ON THE PATENT (print or type)

(1) NAME OF ASSIGNEE:  
SANDOZ LTD.

(2) ADDRESS: (CITY & STATE OR COUNTRY)  
Basle, Switzerland

A  This application is NOT assigned.  
 Assignment previously submitted to the Patent and Trademark Office.  
 Assignment is being submitted under separate cover. Assignments should be directed to Box ASSIGNMENTS.

**PLEASE NOTE:** Unless an assignee is identified in Block 5, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the PTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment.

6a. The following fees are enclosed:  
 Issue Fee  Advance Order - # of Copies \_\_\_\_\_

6b. The following fees should be charged to:  
 DEPOSIT ACCOUNT NUMBER 19-0134  
 (ENCLOSE A COPY OF THIS FORM)  
 Issue Fee  Advance Order - # of Copies 10  
 Any Deficiencies in Enclosed Fees

The COMMISSIONER OF PATENTS AND TRADEMARKS is requested to apply the Issue Fee to the application identified above.

(Authorized Signature) *Thomas O McGovern* (Date) 3/14/97

NOTE: The Issue Fee will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the Patent and Trademark Office.

**Certificate of Mailing**

Note: If this certificate of mailing is used, it can only be used to transmit the Issue Fee. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing.

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Box ISSUE FEE  
Assistant Commissioner for Patents  
Washington, D.C. 20231

on: MARCH 14, 1997 (Date)  
 THOMAS O. MCGOVERN (Name of person making deposit)  
*Thomas O McGovern* (Signature)  
 MARCH 14, 1997 (Date)

DA 1 190134 BA797 142 1290.00  
 DA 1 190134 031797 561 30.00

1 TRANSMIT THIS FORM WITH FEE

#8/C  
5/2/97  
C-style  
76

Case No. 100-7932/PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :  
Sylvain Cottens, et al. : Art Unit: 1202  
Serial No. 08/416,673 : Examiner: R. Bond  
Filed: April 7, 1995 : Batch No.: H50  
For: O-ALKYLATED RAPAMYCIN :  
DERIVATIVES AND THEIR :  
USE, PARTICULARLY AS :  
IMMUNOSUPPRESSANTS :

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on March 14, 1997

(Date of Deposit)

Thomas O. McGovern

Name of applicant, assignee, or Registered Representative

Thomas O. McGovern

Signature

March 14, 1997

Date of Signature

AMENDMENT UNDER 37 CFR 1.312

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Under the provision of 37 CFR 1.312, please amend the above identified application as follows:

IN THE CLAIMS

Please cancel claim 4, 9, and 10.

In line 1 of claims 11 to 15, after the word "claim", delete the number "10", and insert in its place in each instance the number -- 19 --.

In line 1 of claims 11, 12, and 13, after the word "which", delete the term "R<sub>1</sub>", and insert in its place in each instance the term -- R<sup>1</sup> --.

RECEIVED  
Pub. & Trademark  
MAR 17 1997  
04

SL10147 04/17/97 08416673

19-0134 100 142

1,290.00CH

SL10147 04/17/97 08416673

19-0134 100 561


3200CH

C

Claim 16, line 2; claim 17, line 4; and claim 18,  
line 3, after the word "claim", delete the number "10", and  
insert in its place in each instance the number -- 19 --.

Please add the following new claims <sup>18</sup> 19 and <sup>19</sup> 20.

~~178~~ 19. A compound of the formula



wherein R<sup>1</sup> is hydroxy(C<sub>1-6</sub>)alkyl or  
hydroxy(C<sub>1-3</sub>)alkoxy(C<sub>1-3</sub>)alkyl.

~~10~~  
~~19~~ 20. The compound according to claim ~~19~~ which is  
40-O-(3-hydroxyethyl)-rapamycin.

REMARKS

Claims 9 to 18 have been allowed and claims 11 to 20 are now in the application. No additional fee is required.

The instant application was allowed on December 16, 1996; and the issue fee is being submitted concurrently with this amendment.

It is respectfully requested that the above amendments of the claims be entered. The entering of these amendments will not require a new search nor will it require substantial additional work on the part of the Patent and Trademark Office. This Amendment is believed to be proper under the provisions of Rule 312, because it corrects minors errors in the structures and definitions of the claims. Claim 10 has been replaced with new claim 19 to remove the space in the double bond between carbons 17 and 18 in claim 10 and conform the bond to that of the generic compound of formula I on page 2 of the application. Substituent R<sup>1</sup> has been amended in claims 11 to 13 and in new claim 19 to properly identify it. The definition of substituent R<sup>1</sup> has also been amended to limit the alkylene groups of the hydroxyalkoxyalkyl moiety to the preferred C<sub>1-3</sub> alkylene set out on page 3, line 10 of the application. Applicant have added new claim 20 to the application to replace claim 4, which may have been inadvertently deleted from the application instead of claim 9, which was canceled by the Amendment of October 15, 1996.

The proposed amendment do not broaden the scope of the claims or introduce new matter. They were not presented earlier because it was only during a review of the allowed application that it was noted that the amendments were needed. It is therefore respectfully requested that the proposed amendment be entered under the provisions of 35 CFR 1.312.

Respectfully submitted,

By *Thomas O. McGovern*  
Thomas O. McGovern  
Registration No. 25,741  
(201) 503-8480

TOM:lmc

NOVARTIS CORPORATION  
59 Route 10  
E. Hanover, N.J. 07936

March , 1997

Enclosures: COM Stamp; Postcard

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.